Pharsight

Cambia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8097651 ASSERTIO Diclofenac formulations and methods of use
Jun, 2026

(2 years from now)

US7759394 ASSERTIO Diclofenac formulations and methods of use
Jun, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8927604 ASSERTIO Diclofenac formulations and methods of use
Jun, 2026

(2 years from now)

US9827197 ASSERTIO Diclofenac formulations and methods of use
Jun, 2026

(2 years from now)

Cambia is owned by Assertio.

Cambia contains Diclofenac Potassium.

Cambia has a total of 4 drug patents out of which 0 drug patents have expired.

Cambia was authorised for market use on 17 June, 2009.

Cambia is available in for solution;oral dosage forms.

Cambia can be used as acute treatment of migraine attacks with or without aura in adults.

The generics of Cambia are possible to be released after 16 June, 2026.

Drugs and Companies using DICLOFENAC POTASSIUM ingredient

Market Authorisation Date: 17 June, 2009

Treatment: Acute treatment of migraine attacks with or without aura in adults

Dosage: FOR SOLUTION;ORAL

How can I launch a generic of CAMBIA before it's drug patent expiration?
More Information on Dosage

CAMBIA family patents

Family Patents